GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-world Clinical Practice-Reference-Cited by-同舟云学术

GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-world Clinical Practice

Published:2020-02 Issue:2 Volume:42 Page:e1-e12
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Díaz-Trastoy Olaia,Villar-Taibo Rocío,Sifontes-Dubón Mildred,Mozo-Peñalver Hector,Bernabeu-Morón Ignacio,Cabezas-Agrícola José M.,Muñoz-Leira Virginia,Peinó-García Roberto,Martís-Sueiro Aurelio,García-López José M.,Martínez-Olmos Miguel A.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference33 articles.

1. SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination;De Block;Lancet Diabetes Endocrinol,2018

2. A review of the efficacy and safety of oral antidiabetic drugs;Stein;Expert Opin Drug Saf,2013

3. Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a review of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials;Kaul;Diabetes Care,2017

4. Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: symbiotic effects on metabolism and cardiorenal risk;Goncalves;Diabetes Ther,2018

5. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus;DeFronzo;Diabetes,2009

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined Sodium-Glucose-Transporters Inhibitors and Glucagon-Like-Peptide Receptor Agonist Compared With Monotherapy Improves Long-Term Survival: A Real-World Registry;The American Journal of Medicine;2024-08

2. Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies;Cardiovascular Diabetology;2024-03-18

3. Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide;Pharmacological Research;2024-01

4. Does GLP-RA Plus an SGLT2 Inhibitor Yield Greater Weight Loss in Patients with Obesity and Diabetes than Monotherapy?;Current Cardiovascular Risk Reports;2023-08-08

5. All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes;Diabetes, Obesity and Metabolism;2023-06-29